Publikationen in Zusammenarbeit mit Forschern von Universidad Católica de Valencia San Vicente Mártir (16)

2024

  1. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide

    Transplantation and Cellular Therapy, Vol. 30, Núm. 5, pp. 538.e1-538.e10

  2. Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide

    Bone Marrow Transplantation

  3. Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience

    Bone Marrow Transplantation, Vol. 59, Núm. 10, pp. 1376-1386

  4. Single-Unit Transfusion Policy in Autologous Hematopoietic Stem Cell Transplantation: Less is Not Worse

    Transfusion Medicine Reviews, Vol. 38, Núm. 4

2023

  1. Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation

    Transplantation and Cellular Therapy, Vol. 29, Núm. 5, pp. 313.e1-313.e10

  2. Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

    Cancers, Vol. 15, Núm. 8

  3. T Cell-Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia

    Transplantation and Cellular Therapy, Vol. 29, Núm. 5, pp. 322.e1-322.e5

  4. Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution

    Journal of Clinical Medicine, Vol. 12, Núm. 10

2022

  1. Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

    Cancers, Vol. 14, Núm. 8

2017

  1. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

    Neurological Sciences, Vol. 38, Núm. 7, pp. 1213-1221

2015

  1. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

    Leukemia and Lymphoma, Vol. 56, Núm. 2, pp. 415-419

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74

2011

  1. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

    Haematologica, Vol. 96, Núm. 10, pp. 1557-1559

  2. Treatment of multiple myeloma in the elderly: Realities and hopes

    Leukemia and Lymphoma, Vol. 52, Núm. 1, pp. 9-14

2010

  1. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study

    European Journal of Haematology

  2. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

    Transfusion and Apheresis Science, Vol. 43, Núm. 3, pp. 299-303